Jad Chahoud, Chief Scientific and Innovation Officer at Orlando Health Cancer Institute, shared a post on LinkedIn:
“Proud of our team for this Nature Portfolio Communications publication on pembrolizumab + high-dose IL-2 in advanced ccRCC.
This study challenges one of the biggest assumptions in metastatic RCC: not every patient with stage IV disease needs lifelong therapy.
- 73% response rate
- 42% complete responses
- Median OS >84 months
- 42% treatment-free at 5 years
A true first step toward finite-duration immunotherapy for patients with advanced RCC.”
Title: Pembrolizumab plus high-dose IL-2 in advanced clear cell renal cell carcinoma: six-year survival outcomes and molecular signatures from a phase 2 trial
Authors: Jeffrey S. Johnson, Justin W. Miller, Firas Hatoum, Michael J. Schell, Xiaoqing Yu, Gabriel Roman Souza, Sarah Mizelle, Keerthi Gullapalli, Adnan Fazili, Rohit Jain, Jonathan Chatzkel, Ling Cen, Jasreman Dhillon, Christopher Cubitt, Jiqiang Yao, Junmin Whiting, Jiannong Li, Jennifer Swank, Ghazal Jameel, Jingsong Zhang, Xuefeng Wang, Philippe E. Spiess, Mayer Fishman, Jad Chahoud
Read the full article on Nature Communicatons.
Other Articles Featuring Jad Chahoud on OncoDaily.